



Figure S2: observed *versus* predicted response to neratinib in a pharmacogenomic model of 36 breast cancer cell lines, accessed *via* CellminerCDB. Correlations for (A) novel gene signature and (B) gene signature established by Desmedt *et al* 2008 (31) are shown.